Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), Axsome Therapeutics (NASDAQ: AXSM) and Calliditas Therapeutics (NASDAQ: CALT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGNResearch Report), Axsome Therapeutics (AXSMResearch Report) and Calliditas Therapeutics (CALTResearch Report) with bullish sentiments.

Regeneron (REGN)

In a report released today, Michael King from H.C. Wainwright maintained a Buy rating on Regeneron, with a price target of $831.00. The company’s shares closed last Tuesday at $645.15.

According to TipRanks.com, King is a 5-star analyst with an average return of 27.7% and a 58.6% success rate. King covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Werewolf Therapeutics, and Agios Pharma.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regeneron with a $714.08 average price target, which is an 11.6% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $690.00 price target.

See today’s analyst top recommended stocks >>

Axsome Therapeutics (AXSM)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Axsome Therapeutics, with a price target of $180.00. The company’s shares closed last Tuesday at $26.17, close to its 52-week low of $19.38.

According to TipRanks.com, Selvaraju is a 2-star analyst with an average return of 0.5% and a 39.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, NeuroBo Pharmaceuticals, and Fennec Pharmaceuticals.

Currently, the analyst consensus on Axsome Therapeutics is a Moderate Buy with an average price target of $93.75.

Calliditas Therapeutics (CALT)

H.C. Wainwright analyst Edwin Zhang maintained a Buy rating on Calliditas Therapeutics today and set a price target of $52.00. The company’s shares closed last Tuesday at $24.48.

According to TipRanks.com, Zhang has 0 stars on 0-5 stars ranking scale with an average return of -21.4% and a 6.3% success rate. Zhang covers the Healthcare sector, focusing on stocks such as Aldeyra Therapeutics, Liminal BioSciences, and FibroGen.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Calliditas Therapeutics with a $46.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.